Sign in

CIK 0001652130

  • Large accelerated filer

Intellia Therapeutics, Inc.

Sign in to watch
Ticker
NTLA
Exchange
Nasdaq
Industry
In Vitro & In Vivo Diagnostic Substances
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
364785571
Phone
+1 857-285-6200
Business address
400 TECHNOLOGY SQUARE, SUITE 100, CAMBRIDGE, MA
  1. 4 Open-market sale EVP, Chief Scientific Officer sold 8,966 shares at $12.18 ($109,206)
  2. 4 Open-market sale EVP, Chief Technical Officer sold 7,978 shares at an average $12.17 ($97,089)
  3. 4 Exercise or conversion EVP, Chief Medical Officer acquired 3,189 shares (option exercise)
  4. 4 Exercise or conversion President and CEO acquired 7,850 shares (option exercise)
  5. 4 Exercise or conversion EVP, Chief Scientific Officer acquired 3,500 shares (option exercise)
  6. 4 Open-market sale VP, Chief Accounting Officer sold 2,012 shares at $19.01 ($38,248)
  7. 4 Grant or award EVP, Chief Financial Officer acquired 66,324 shares (grant or award)
  8. 3 Insider Initial Statement of Ownership
  9. 4 Open-market sale EVP, Chief Technical Officer sold 405 shares at $22.93 ($9,287)
  10. 4 Grant or award VP, PAO and Interim PFO acquired 17,801 shares (grant or award)
  11. 4 Planned sale Director sold 1,505 shares at $25.00 ($37,625)
  12. 3 Insider Initial Statement of Ownership
  13. 4 Grant or award Director acquired 15,409 shares (grant or award)
  14. 4 Grant or award Director acquired 7,737 shares (grant or award)
  15. 4 Grant or award Director acquired 7,737 shares (grant or award)
  16. 4 Grant or award Director acquired 7,737 shares (grant or award)
  17. 4 Grant or award Director acquired 7,737 shares (grant or award)
  18. 4 Grant or award Director acquired 7,737 shares (grant or award)
  19. 4 Grant or award Director acquired 7,737 shares (grant or award)
  20. 3 Insider Initial Statement of Ownership

Page 4 of 18 · 353 filings